Novo Nordisk, the largest insulin player of the world, announced on 2 September 2013 that it was launching the long-lasting insulin injection Tresiba in India in the near future. The company announced that the clinical trials were over and that the approvals were already received. Tresiba will be launched by the end of 2013.
What is Tresiba?
• Tresiba (insulin degludec) is the new basal insulin meant for type 1 and type 2 adult diabetic patients. It will be available in India as the new diabetes treatment option.
• The duration of action of Tresiba is beyond 42 hours, which enables flexibility in day-to-day dosing time as and when required. It will also help in avoiding the risk of hypoglycaemia.
• At present, the insulin treatments demand the diabetic patients to take the long-acting insulin at same time every day. However, in case of this new insulin, it is easy to compromise on this matter on the occasions when it is not possible to take the insulin at the same time every day. Therefore, Tresiba (insulin degludec) enables one to avoid increased risk of hypoglycaemia.
• Tresiba will be available in India in prefilled pen which will have easy touch button, thereby enabling the dioses to increase up to 80 units in the single injection.
It is important to note that Novo Nordisk India holds 15 percent of market share in the diabetes care segment.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.